June 11, 2019
Novartis Pharma said on June 10 that its anti-IgE antibody Xolair (omalizumab) demonstrated a statistically significant improvement versus placebo in a Japan PIII study covering patients with severe cedar pollen allergy inadequately controlled with existing treatments. In the study, which...read more